iwCLL 2023 | Zanubrutinib in patients with CLL intolerant to ibrutinib and acalabrutinib
In this video, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on BGB-3111-215, a Phase II trial (NCT04116437) evaluating zanubrutinib in patients with B-cell malignancies who have previously exhibited intolerance to ibrutinib and/or acalabrutinib, which has resulted in discontinuation of treatment. Dr Shadman focuses on patients with chronic lymphocytic leukemia (CLL) and elucidates that based on current data from the trial, most patients do not have recurrence of prior adverse events (AEs) experienced on ibrutinib and/or acalabrutinib when taking zanubrutinib. In those where AEs do reoccur, they are of a lower or equal grade. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MEI Pharma: Consultancy; Fate Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Innate Pharma: Consultancy; Epi Lilly: Consultancy; Adaptimmune: Consultancy; AstraZeneca: Consultancy, Research Funding; Epizyme: Consultancy; Mustang Bio: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Regeneron: Consultancy; Merck: Consultancy; Adaptive Biotechnologies: Consultancy; Morphosys/Incyte: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Sound Biologics: Consultancy; Kite Pharma: Consultancy; Abbvie: Consultancy, Research Funding; Atara Biotherapeutic: Consultancy, Research Funding; Celgene, a BMS Company: Research Funding; Gilead: Research Funding; Sunesis: Research Funding; Genmab: Research Funding.
